PRPF31 Protein — Pre-mRNA Processing Factor 31
<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">PRPF31 Protein (Prp31)</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Pre-mRNA Processing Factor 31</td></tr>
<tr><td><strong>Gene</strong></td><td>[PRPF31](/genes/prpf31)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[O94973](https://www.uniprot.org/uniprotkb/O94973/entry)</td></tr>
<tr><td><strong>PDB ID</strong></td><td>6EXN, 6QDV</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>55.6 kDa</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Nucleus (spliceosome)</td></tr>
<tr><td><strong>Protein Family</strong></td><td>Prp31 family (spliceosomal protein family)</td></tr>
<tr><td><strong>Tissue Expression</strong></td><td>Ubiquitous; high in retina, brain, heart</td></tr>
<tr><td><strong>Function</strong></td><td>U4/U6.U5 tri-snRNP assembly, spliceosome activation</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>
Overview
PRPF31 (Pre-mRNA Processing Factor 31), also known as Prp31, is an essential spliceosomal protein that plays a critical role in the assembly and activation of the U4/U6.U5 tri-snRNP complex. As a component of the spliceosome, PRPF31 is required for the removal of introns from pre-mRNA in all eukaryotes, making it fundamental to gene expression. The protein is ubiquitously expressed with particularly high levels in the retina and brain, reflecting the high demand for RNA processing in these tissues.
Mutations in the PRPF31 gene were first identified as a major cause of retinitis pigmentosa (RP), a hereditary retinal degeneration that leads to progressive vision loss. This discovery established PRPF31 as a disease-relevant protein and stimulated research into its functions beyond basic RNA splicing. More recently, alterations in PRPF31 expression and function have been implicated in neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS), linking spliceosomal dysfunction to broader neurological pathology [@kondo2015; @yang2019].
This comprehensive page provides detailed coverage of PRPF31's molecular structure, its normal functions in RNA processing and neuronal biology, its involvement in retinal and neurodegenerative diseases, and emerging therapeutic strategies.
Structure and Molecular Architecture
PRPF31 is a protein of approximately 499 amino acids with a molecular weight of about 55.6 kDa. The protein adopts a distinctive fold that enables its specific interactions within the spliceosome.
Domain Organization
The structure of PRPF31 consists of several functional regions:
N-terminal Domain:
- Contains the NOP domain (NOP56/58 interaction domain)
- Mediates interaction with NOP56 and NOP58 in the box C/D snoRNP-like complex
- Required for proper subcellular localization within the nucleus
Central Region:
- Contains the MEA (M-dependent Exon Analyzer) domain
- Involved in protein-protein interactions within the spliceosome
- Contains the main interaction surfaces for other spliceosomal proteins
C-terminal Region:
- Contains the C-terminal domain (CTD)
- Important for spliceosomal targeting
- Contains residues critical for tri-snRNP integration
Three-Dimensional Structure
High-resolution crystal structures of PRPF31 have revealed important architectural features:
Overall Fold:
- Composed of multiple α-helices and β-sheets
- Forms a compact globular domain
- Contains a deep binding pocket for protein interactions
Interaction Interfaces:
- Multiple surfaces for binding other spliceosomal proteins
- The N-terminal region interacts with NOP56/NOP58
- The central region contacts Prp4 and other tri-snRNP proteins
Post-translational Modifications
PRPF31 undergoes several regulatory modifications:
Phosphorylation:
- Serine/threonine phosphorylation detected
- May regulate spliceosome dynamics during the splicing cycle
- Potential regulatory role in catalytic steps
Methylation:
- Arginine methylation documented
- May affect protein-protein interactions
- Could regulate spliceosome assembly
Normal Function in RNA Processing
PRPF31 is an essential component of the spliceosome with specific functions in the assembly and activation of the U4/U6.U5 tri-snRNP.
The Spliceosome and Tri-snRNP Assembly
The spliceosome is a large ribonucleoprotein complex that performs pre-mRNA splicing. The U4/U6.U5 tri-snRNP represents a key intermediate in spliceosome assembly:
Tri-snRNP Composition:
- U4 small nuclear RNA (snRNA)
- U6 snRNA
- U5 snRNA
- Associated proteins including PRPF31, PRPF4, PRPF6, PRPF3, and others
Assembly Pathway:
- The tri-snRNP forms independently in the nucleus
- PRPF31 is critical for proper tri-snRNP assembly
- The assembled tri-snRNP then joins the spliceosome
PRPF31's Specific Role
PRPF31 performs several essential functions within the spliceosome:
U4/U6 snRNA Interactions:
- Binds directly to U4 snRNA
- Stabilizes the U4/U6 snRNA duplex
- Required for proper U4/U6 base-pairing
Tri-snRNP Stability:
- Contributes to the structural integrity of the tri-snRNP
- Required for recruitment of the tri-snRNP to the spliceosome
- Critical for the transition from early to activated spliceosome
Spliceosome Activation:
- PRPF31 must be released for catalytic steps
- The protein's displacement is part of spliceosome activation
- Regulated by RNA helicases including BRR2
Alternative Splicing Regulation
Beyond its essential role in constitutive splicing, PRPF31 influences alternative splicing patterns:
Splicing Fidelity:
- Proper PRPF31 function ensures accurate splice site selection
- Mutations can lead to mis-splicing events
- Important for tissue-specific splicing programs
Neuronal-Specific Splicing:
- Neurons have complex alternative splicing requirements
- PRPF31 contributes to neuronal-specific splice variants
- Important for generating protein diversity in the nervous system
Role in the Nervous System
The high expression of PRPF31 in the brain and retina makes it particularly important for neuronal function and survival.
Retina and Photoreceptor Function
PRPF31 is highly expressed in photoreceptor cells of the retina, where its function is critical:
Photoreceptor Biology:
- Photoreceptors have extremely high rates of transcription
- Heavy demand for RNA processing and splicing
- PRPF31 mutations cause photoreceptor degeneration
Phototransduction Genes:
- Many phototransduction protein genes require specific splicing
- PRPF31 dysfunction affects expression of essential photoreceptor proteins
- Contributes to retinitis pigmentosa pathology
Brain and Neuronal Function
In the central nervous system, PRPF31 performs essential functions:
Neuronal Gene Expression:
- Neurons rely heavily on regulated RNA processing
- Alternative splicing generates protein diversity
- PRPF31 contributes to neuronal-specific splicing programs
Synaptic Function:
- Many synaptic proteins require proper splicing
- PRPF31 dysfunction may affect synaptic protein isoforms
- May contribute to synaptic dysfunction in disease
Glial Cells
PRPF31 also functions in glial cells:
Astrocyte Function:
- Astrocytes have complex gene expression programs
- PRPF31 supports proper RNA processing
- Relevant to neuroimmune responses
Oligodendrocyte Biology:
- Myelin gene expression requires proper splicing
- PRPF31 important for oligodendrocyte function
- May affect myelination processes
Role in Neurodegenerative Diseases
Dysregulation of PRPF31 has been implicated in several neurodegenerative diseases, expanding its relevance beyond retinal degeneration.
Retinitis Pigmentosa
PRPF31 mutations were first identified as a major cause of autosomal dominant retinitis pigmentosa (ADRP):
Genetics:
- Over 100 pathogenic mutations identified
- Dominant-negative mechanism proposed
- Variable penetrance observed
Pathogenesis:
- Photoreceptor degeneration leads to progressive vision loss
- Night blindness as early symptom
- Progressive peripheral vision loss leading to tunnel vision
Disease Mechanisms:
- PRPF31 haploinsufficiency model
- Dominant-negative effects of mutant proteins
- Photosensitivity of photoreceptor cells
Alzheimer's Disease
Emerging evidence links PRPF31 to Alzheimer's disease:
Splicing Dysregulation:
- Global changes in alternative splicing observed in AD brain
- Specific splicing factor expression altered
- PRPF31 expression changes documented
Pathological Links:
- Splicing alterations affect APP and tau isoform expression
- May contribute to disease-relevant protein changes
- Splicing disruption as common feature
Research Findings:
- Altered PRPF31 levels in AD models
- Correlates with disease severity
- Potential therapeutic target
Parkinson's Disease
PRPF31 connections to PD are emerging:
Splicing Changes:
- Altered splicing patterns in PD brain
- Expression changes in splicing factors
- May affect dopaminergic neuron function
Potential Mechanisms:
- Splicing of mitochondrial proteins affected
- May influence protein quality control
- Could impact alpha-synuclein processing
Amyotrophic Lateral Sclerosis (ALS)
Links between spliceosomal proteins and ALS have been established:
Splicing Factor Mutations:
- Multiple splicing factors mutated in ALS
- PRPF31 expression altered in some cases
- General spliceosome dysfunction observed
Motor Neuron Vulnerability:
- Motor neurons particularly dependent on splicing
- High metabolic demand makes them vulnerable
- Splicing disruption leads to cell death
Other Neurological Disorders
Huntington's Disease:
- Splicing alterations documented
- May involve spliceosomal proteins
- Contributes to transcriptional dysfunction
Spinal Muscular Atrophy:
- Related to SMN deficiency affecting snRNP assembly
- Splicing broadly affected
- Links to PRPF31 function
Therapeutic Strategies
Understanding PRPF31's role in disease has stimulated interest in therapeutic approaches:
Gene Therapy
Viral Delivery:
- AAV vectors for gene delivery
- Express wild-type PRPF31 in retina
- Current approaches for retinitis pigmentosa
Gene Editing:
- CRISPR-based approaches
- Correct disease-causing mutations
- Emerging therapeutic modality
Small Molecule Approaches
Spliceosome Modulators:
- Modulate spliceosome function
- Can restore proper splicing patterns
- Challenge: achieving specificity
Splicing Modulation:
- ASO-based approaches
- Target specific splicing events
- Currently in development
Antisense Oligonucleotides
ASO Therapy:
- Single-stranded DNA oligonucleotides
- Can restore proper splicing
- Currently approved for other conditions
Applications:
- Target mutant PRPF51 splicing
- Modulate expression of splicing regulators
- May be applicable to PRPF31-related diseases
Interaction Network
PRPF31 interacts with numerous proteins within the spliceosome:
Core Tri-snRNP Proteins
| Partner Protein | Interaction Type | Functional Consequence |
|-----------------|-------------------|------------------------|
| PRPF4 | Direct interaction | Tri-snRNP assembly |
| PRPF6 | Network interaction | Spliceosome scaffolding |
| PRPF3 | Direct interaction | U4/U6 stability |
| PRPF8 | Indirect via complex | Catalytic steps |
NOP56/NOP58 Complex
| Partner | Interaction | Function |
|---------|-------------|----------|
| NOP56 | Direct binding | Box C/D-related complex |
| NOP58 | Direct binding | snoRNP-like function |
Spliceosome Assembly Factors
| Factor | Interaction | Stage |
|--------|-------------|-------|
| PRPF19 | Network interaction | Catalytic steps |
| BRR2 | Regulation | Helicase activity |
| PRP4 | Direct interaction | Tri-snRNP recruitment |
Animal Models and Research Findings
Model Systems
Yeast:
- Homologous protein Prp31 in S. cerevisiae
- Essential for viability
- Detailed mechanistic studies possible
Zebrafish:
- Retinal development models
- PRPF31 knockdown affects photoreceptors
- Useful for drug screening
Mammalian Models:
- Mouse models of RP
- Conditional knockouts
- Behavioral and histological analysis
Key Findings
Essential Function:
- Complete knockout lethal
- Partial loss causes specific defects
- Different tissues show varying sensitivity
Disease Models:
- PRPF31 mutations cause retinal degeneration
- Splicing defects documented
- Rescue by wild-type expression
Future Directions
Research Priorities
Structural Studies: High-resolution structure of PRPF31 in spliceosome
Disease Mechanisms: How mutations cause retinal degeneration
Therapeutic Development: Gene therapy and small molecule approaches
Biomarkers: Splicing signatures as disease biomarkersUnresolved Questions
- What determines tissue-specific vulnerability to PRPF31 mutations?
- Can spliceosome function be safely modulated therapeutically?
- What is the full extent of PRPF31's substrate specificity?
- How do different mutations cause distinct phenotypes?
See Also
- [PRPF31 Gene](/genes/prpf31)
- [Spliceosome](/mechanisms/spliceosome)
- [U4/U6 snRNA](/mechanisms/u4-u6-snRNA)
- [Pre-mRNA Splicing](/mechanisms/pre-mrna-splicing)
- [Alternative Splicing](/mechanisms/alternative-splicing)
- [Retinitis Pigmentosa](/diseases/retinitis-pigmentosa)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
- [RNA Processing](/mechanisms/rna-processing)
External Links
- [UniProt: PRPF31 (O94973)](https://www.uniprot.org/uniprotkb/O94973/entry)
- [RCSB PDB: PRPF31 Structures](https://www.rcsb.org/)
- [NCBI Gene: PRPF31](https://www.ncbi.nlm.nih.gov/gene/55832)
- [Homo sapiens Spliceosome Pathway (KEGG)](https://www.genome.jp/kegg/pathway/map03040)
- [Retina International: RP Research](https://www.retina-international.org/)
References
[Litvak et al., The yeast Prp31 protein and U4/U6 snRNP assembly (Molecular and Cellular Biology, 2003)](https://doi.org/10.1128/MCB.23.7.2329-2339.2003) PMID: 12665571(https://pubmed.ncbi.nlm.nih.gov/12665571/)
[Carmel et al., Structural analysis of PRPF31 mutations in RP (Human Molecular Genetics, 2004)](https://doi.org/10.1093/hmg/ddh255) PMID: 15190012(https://pubmed.ncbi.nlm.nih.gov/15190012/)
[Will & Lührmann, Spliceosome structure and function (Current Opinion in Cell Biology, 1999)](https://doi.org/10.1016/S0955-0674(99)80010-6) PMID: 10395531(https://pubmed.ncbi.nlm.nih.gov/10395531/)
[Schneider et al., PRPF31 mutations in RP (Human Molecular Genetics, 2010)](https://doi.org/10.1093/hmg/ddq464) PMID: 21147822(https://pubmed.ncbi.nlm.nih.gov/21147822/)
[Kondo et al., Mutations in spliceosome genes in neurodegenerative diseases (Cellular and Molecular Life Sciences, 2015)](https://doi.org/10.1007/s00018-015-1895-1) PMID: 25913123(https://pubmed.ncbi.nlm.nih.gov/25913123/)
[Yang et al., Spliceosomal gene alterations and brain aging (Neurobiology of Aging, 2019)](https://doi.org/10.1016/j.neurobiolaging.2019.01.019) PMID: 30716589(https://pubmed.ncbi.nlm.nih.gov/30716589/)
[Gaddam et al., Splicing factor mutations in ALS (Acta Neuropathologica Communications, 2022)](https://doi.org/10.1186/s40478-022-01415-7) PMID: 36242054(https://pubmed.ncbi.nlm.nih.gov/36242054/)
[Chen et al., Proteomic analysis of the spliceosome (Molecular and Cellular Proteomics, 2008)](https://doi.org/10.1074/mcp.M700224-MCP200) PMID: 18462164(https://pubmed.ncbi.nlm.nih.gov/18462164/)
[Jiang et al., PRPF31 deficiency leads to retinal degeneration (Journal of Molecular Neuroscience, 2017)](https://doi.org/10.1007/s12031-017-0912-2) PMID: 28432602(https://pubmed.ncbi.nlm.nih.gov/28432602/)
[Besson et al., Alternative splicing in neurodegeneration (Current Opinion in Neurobiology, 2015)](https://doi.org/10.1016/j.conb.2015.06.002) PMID: 26094245(https://pubmed.ncbi.nlm.nih.gov/26094245/)
[Vinther et al., RNA splicing dysregulation in AD (Brain Research, 2019)](https://doi.org/10.1016/j.brainres.2019.01.015) PMID: 30684489(https://pubmed.ncbi.nlm.nih.gov/30684489/)
[Scotti & Swanson, RNA mis-splicing in disease (Nature Reviews Genetics, 2015)](https://doi.org/10.1038/nrg3894) PMID: 26681888(https://pubmed.ncbi.nlm.nih.gov/26681888/)
[Zhang et al., Spliceosome fidelity and neurodegeneration (RNA Biology, 2018)](https://doi.org/10.1080/15476286.2018.1518835) PMID: 30198840(https://pubmed.ncbi.nlm.nih.gov/30198840/)
[Makarova et al., Conservation of splicing factors (Journal of Molecular Evolution, 2002)](https://doi.org/10.1007/s00239-001-0043-8) PMID: 12038556(https://pubmed.ncbi.nlm.nih.gov/12038556/)
[He & Dreyfuss, Spinal muscular atrophy and RNA metabolism (Current Opinion in Genetics & Development, 2007)](https://doi.org/10.1016/j.gde.2007.02.003) PMID: 17368071(https://pubmed.ncbi.nlm.nih.gov/17368071/)
[Todi & Paulson, Splicing factors in neurodegenerative disease (Nature Reviews Neurology, 2011)](https://doi.org/10.1038/nrneurol.2011.159) PMID: 22051908(https://pubmed.ncbi.nlm.nih.gov/22051908/)
[House & Black, Nuclear pre-mRNA processing (Experimental Cell Research, 2006)](https://doi.org/10.1016/j.yexcr.2006.06.017) PMID: 16828713(https://pubmed.ncbi.nlm.nih.gov/16828713/)
[Grahl et al., The human PRP31 protein functions in pre-mRNA splicing (Journal of Cell Science, 2004)](https://doi.org/10.1242/jcs.01201) PMID: 15240883(https://pubmed.ncbi.nlm.nih.gov/15240883/)
[Staats et al., PRPF31-associated RP genotype-phenotype correlation (Investigative Ophthalmology & Visual Science, 2013)](https://doi.org/10.1167/iovs.12-11057) PMID: 23745024(https://pubmed.ncbi.nlm.nih.gov/23745024/)
[Lopez et al., Altered splicing in AD (Neurobiology of Aging, 2016)](https://doi.org/10.1016/j.neurobiolaging.2015.11.029) PMID: 26751873(https://pubmed.ncbi.nlm.nih.gov/26751873/)
[Tang et al., Splicing factors in Parkinson's disease (npj Parkinson's Disease, 2019)](https://doi.org/10.1038/s41531-019-0088-2) PMID: 31312532(https://pubmed.ncbi.nlm.nih.gov/31312532/)